Skip to main content
. 2019 Jan 1;10(1):17–29. doi: 10.18632/oncotarget.26523

Figure 5. Overview of systemic therapy sequence and tumor marker chromogranin A (CgA) of a patient with metastatic prostatic well differentiated NET (carcinoid).

Figure 5

Insert: representative DOTATOC-PET/CT scan showing somatostatin receptor positive lesions. EVE: everolimus; PRRT: peptide receptor radionuclide therapy; ULN: upper limit normal.